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Edited by Takashi GojoboriAbstract Sequence-speciﬁc gene silencing by double-strand
RNA has been observed in many eukaryotes. Accumulating data
suggest that it is the major antiviral defense mechanism in plants
and invertebrates. The discovery that this cellular mechanism is
also highly conserved though somewhat impaired in mammals
has stimulated debate about the evolution of antiviral systems.
Here we suggest that the existence of the interferon response
as an evolutionary intermediate could account for both the rela-
tive decline of RNA silencing and the development of protein-
based immune systems in vertebrates. In addition, we emphasize
the opportunities presented by RNA silencing and the deeper
understanding of vertebrate antiviral systems that is needed.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RNA silencing or post-transcriptional gene silencing (PTGS)
is a process of degradation of cognate mRNA in response to
the introduction of a double-strand RNA (dsRNA). It is com-
monly accepted that RNA silencing is the major antiviral de-
fense system in plants and invertebrates. The important role
of short dsRNA molecules in initiating sequence-speciﬁc gene
silencing was ﬁrst discovered in the nematode Caenorhabditis
elegans [1]. This process, also termed RNA interference
(RNAi), is mediated by small interfering RNAs (siRNAs)
(19–27 bp long), which are generated by cleavage of dsRNA
by an RNaseIII-like enzyme, Dicer [2]. There is recent evidence
that this form of gene silencing is conserved in mammals [3–5].
These remarkable observations have led to demonstrations of
a protective eﬀect of siRNAs against mammalian viruses,
although it has been reported that siRNAs also activate the
protein kinase R (PKR)-RNase L pathway [6,7], an important
innate antiviral mechanism regulated by interferon (IFN) [8].
These ﬁndings raise a number of questions. Does RNAi oc-
cur naturally in virally infected cells of vertebrates thus repre-
senting a nucleic acid-based immune system, by analogy with*Corresponding author. Fax: +86 21 65642504.
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ship between the two, are they quite separate or linked in some
way? Why is this antiviral system in mammalian cells not pow-
erful enough to combat viral infection on its own without the
artiﬁcial introduction of siRNAs? How can we achieve a better
understanding of the capacity of vertebrates to defend against
viruses? What new approaches might lead to more eﬀective
procedures for treating vertebrate viral diseases?2. RNAi as a natural antiviral mechanism
Li et al. [9] postulated that RNA silencing is a natural anti-
viral response in mammals. Their hypothesis is supported by
three lines of evidence: ﬁrst, the RNA silencing machinery is
conserved in mammals and can inhibit viral infection when
the formation of siRNAs is experimentally induced. Second,
mammalian viruses encode suppressors (e.g., the E3L and
NS1 proteins by the inﬂuenza and vaccinia viruses) of RNAi
as an essential feature, as has been established for viruses of
plants and invertebrates. Third, suppressors of RNAi also
act as inhibitors of the innate mammalian antiviral response
regulated by the IFN system.
These discoveries not only suggest a strategy for treating
viral diseases in mammals but also promise a deeper under-
standing of the evolution of mammalian antiviral potential.
Biology students are taught that the classical protein-based im-
mune response is the major antiviral mechanism in vertebrates.
Nevertheless there is increasing evidence that RNA silencing is
an evolutionarily conserved mechanism that protects genomes
from exogenous (viral) and endogenous (transposon) invasion,
and impacts on cellular programs of gene expression and
development [10–12]. Both protein-based and siRNA-based
mechanisms at least in part share the same function, namely
combating invaders. These facts prompted us to consider the
evolutionary relationship between them. Table 1 compares
the features of RNAi and of vertebrate protein-based immune
systems. They are comparable in at least seven crucial aspects,
some of which had been described by Ding et al. [13]. In addi-
tion, dsRNA (and even siRNA), induces a non-speciﬁc antivi-
ral response involving the PKR-RNase L pathway, similar to
that mediated by cytokines in protein-based immune systems.
Furthermore, RNA silencing leads to non-cytopathic viral
clearance [14,15], whereas the protein-based immune response
brings about widespread microphagocytosis or apoptosis of vi-
rally infected cells [16].blished by Elsevier B.V. All rights reserved.
Table 1
Comparison of protein-based immune systems and RNA silencing
Features Protein-based immune
system
RNA silencing
1 Antigen Viral genome/transposon/
aberrant RNAs/mRNA
expressed from plasmid
backbones
2 Antibody siRNA
3 Lymphocytes (B- and T-cells) Dicer/RISCa
4 Cytokines (IL, IFN, etc.) PKR/RNase L/IFN
pathways
5 Microphagocytosis/apoptosis Non-cytopathic viral
clearance
6 Immunological memory A rudimentary form of
memory
7 Immune response (several
days to a few months)
RNAi eﬀect (several
hours to a few days)
aIn animal RNAi pathways, target RNA destruction is catalyzed by
the siRNA-guided, RNA-induced silencing complex (RISC).
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evolved prior to the appearance of the protein-based immune
system of vertebrates [10]. Many scientists have suggested that
life originated as an RNA world and have proposed models of
the evolution of life from the late stages of the RNA world to
the emergence of eukaryotes and prokaryotes [17–19]. In the
hypothetical RNA world, RNA had both genotypic and phe-
notypic capabilities. RNAi is a mechanism in which gene-
speciﬁc dsRNA triggers the degradation of corresponding
transcripts. The observations that Entamoeba histolytica and
Giardia intestinalis have RNAi pathways and that RNAi genes
are present in Giardia support the view that gene silencing by
dsRNA appeared very early in the evolution of the eukaryotic
lineage [20]. Interestingly, Billy et al. [3] have demonstrated
that extracts of embryonal carcinoma (EC) P19 and F9 cells
contain much higher levels of Dicer than extracts of diﬀerenti-
ated cells such as rat REF52, mouse NIH 3T3 or human Hela
cells. Moreover, these researchers showed that speciﬁc RNAi
could be induced by long dsRNA in mouse embryonal terato-
carcinoma cell lines, whereas induction of RNAi in response to
long dsRNA has generally been unsuccessful in diﬀerentiated
mammalian cells, most likely due to non-speciﬁc eﬀects of
dsRNA-dependent PKR and RNase L, both of which are
eﬀectors of the IFN response [21]. It is well known that pro-
tein-based immune systems cannot function as strong defenses
against invaders early in mammalian embryogenesis. These
phenomena also imply that RNA silencing, which acts as the
major natural antiviral mechanism in plants and invertebrates,
could have become somewhat defective and have eventually
been functionally replaced by a superior protein-based im-
mune system during the evolution of vertebrates.
At present there is no evidence that RNAi is employed in
bacterial and archeal cells; hence one needs to be cautious in
suggesting a very early origin of RNAi. However, the existence
of ribozymes (or catalytic RNAs) discovered a little more than
20 years ago is suggestive [22]. Ribozymes catalyze sequence-
speciﬁc reactions (cleavage or ligation of the RNA phosphodi-
ester backbone) controlled by RNA–RNA interactions
between the ribozyme and its substrate molecules [23]. They
occur widely in viruses, bacteria, plants, and lower eukaryotes,
but are rare in vertebrates. The structure and functional simi-larity, and cell type distribution of ribozymes and RNA silenc-
ing machinery inevitably suggest the idea that RNAi is a
mechanism that evolved from a primordial molecular informa-
tion-processing system such as ribozymes. To test this hypoth-
esis, it will be necessary to look for possible intermediates in
lower species.3. RNAi could be a co-agent of protein-based immune systems in
vertebrates
Gitlin and Andino [10] have discussed the possibility that
RNA silencing, as a versatile antiviral system, may have been
conserved during evolution, since viruses (as well as other
molecular parasites like transposons) probably maintain an
unrelenting selective pressure on their hosts, despite the fact
that vertebrates have evolved a sophisticated immune mecha-
nism based on protein recognition. Since an impressive num-
ber of RNAi eﬀects involving viral infection of mammals
have been demonstrated [14,24–28], we wish to emphasize
the possibility that RNA silencing acts synergistically with
conventional mammalian protein-based immune systems in de-
fense against viruses.
As described in Table 1, RNA silencing based on recognition
at the level of RNA, and sequence-speciﬁc and rapid inhibition
of viral infection, could complement and strengthen protein-
based immunity in controlling important vertebrate patho-
gens. First, RNAi has been shown to occur in the cytoplasm
[29,30], where protein-based recognition of virus by lympho-
cytes, antibodies and cytokines cannot take place. RNA silenc-
ing can be triggered by viruses or transposons that generate
dsRNA during their replication [31], and aberrant RNAs that
have not been well characterized are thought to be capable of
initiating RNAi responses in plants. Second, as mentioned,
RNAi as a natural antiviral mechanism involves non-cyto-
pathic viral clearance [14,15], whereas the protein-based im-
mune response induces broad range microphagocytosis, or
apoptosis, of virally infected cells [16]. Moreover, viral infec-
tions, acting on the protein-based immune system, can ablate
self-tolerance, mimic immune responses to self-antigens, and
induce autoimmune disease [32–34]. Third, RNAi leads to ra-
pid and eﬃcient resistance against viral infection in response to
siRNA [35] and can achieve relatively long lasting viral sup-
pression in mammalian cells [36], whereas it takes traditional
vaccines based on inactivated virus or subunit peptides a few
days to induce an immune response strong enough to prevent
disease; even so-called emergency vaccines require 4–5 days to
elicit suﬃcient levels of interfering factors to achieve protec-
tion [37].
Is it possible that siRNAs generated by viral infection, chem-
ical synthesis or direct transcription from vectors (plasmid or
virus), could help to develop protein-based immunity? Previ-
ous work by Suzuki et al. [38] showed that the introduction
of fragments of dsRNA as short as 25 bp in length into the
cytoplasm of non-immune cells could cause abnormal expres-
sion of the major histocompatibility complex (MHC), as well
as the expression or activation of other genes or gene products
essential for antigen presentation. This eﬀect was sequence-
independent, not duplicated by single-stranded polynucleo-
tides, and control experiments eliminated the involvement of
CpG motifs, which act directly on cells of the immune system.
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cause normal cells such as rat FRTL-5 thyroid cells to become
‘‘non-professional’’ antigen-presenting cells (APCs) and triggerFig. 1. A brief schematic representation of the antiviral responses in
vertebrates. In addition to the lymphocytes, the non-immune cells have
been employed to elicit antiviral response in speciﬁc or non-speciﬁc
manner, due to activation by dsDNA and dsRNA generated by viral
infection or artiﬁcial methods. The non-speciﬁc response has shown an
interaction between the non-immune cells and the protein-based
immune system. A role of RNA silencing in inducing the immuno-
sitmulatory eﬀect to or immunosurveillance by the traditional system
should be further determined.
Fig. 2. Representation of the relative activity of antiviral mechanisms in
conserved in mammals and naturally induced by viral infection, the potential
(A) development of mammals as a whole, (B) embryo period when challenged
period with an artiﬁcially established RNA silencing.immunosurveillance of these cells by activating cells of the im-
mune system [38,39]. In the case of RNAi, the initial dsRNA is
cleaved to siRNAs, 19–27 nucleotides long, by a protein com-
plex containing Dicer [2], and induction of an IFN response by
siRNAs or RNAi vectors has been reported in mammalian
cells [6,7,40,41]. IFNs are involved in numerous immune inter-
actions during viral infection, and contribute to both the
induction and regulation of innate and adaptive antiviral
mechanisms [8]. Thus, it will be important to seek evidence
for the involvement of siRNAs in protein-based immune sys-
tems (Fig. 1).4. The IFN response: A bridge between RNA silencing and
protein-based immune systems?
There is evidence of antiviral synergy between the RNAi
machinery and the IFN response during embryogenesis (Fig.
2). In embryonic cells of mammals, RNA silencing can be eﬃ-
ciently and speciﬁcally induced by even long dsRNA, presum-
ably due to the high level of Dicer expression, and induction of
IFN genes by dsRNA or viral infection is defective because of
a lack of dsRNA- and IFN-activated enzymes [42–46]. In dif-
ferentiated cells, however, the speciﬁc RNAi eﬀect seems to be
impaired due to downregulation of Dicer expression [3], while
IFN-a/b is produced rapidly in the early phase of a viral infec-
tion when viral factors interact with cellular pattern-recogni-
tion receptors (PRRs) [8]. Both RNA silencing and the IFN
response confer rapid resistance during the early phase of viral
infection. These results suggest that these two systems syner-
gize in their antiviral actions. Future work will be necessary
to determine if virus infection indeed elicits an RNA silencingvertebrates. Based on the hypothesis that RNA silencing would be
ities of three antiviral mechanisms employed is simply described during
with virus, (C) adult period when challenged with virus, and (D) adult
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than the IFN response or protein-based immunity (Fig. 2B).
Furthermore, we suggest that the IFN response may have
played a key role in the evolutionary development of pro-
tein-based immune systems, and that it served as a bridge be-
tween this adaptive system and RNA silencing during the
evolution of antiviral mechanisms. The following is a summary
of the published studies and theoretical ideas supporting this
hypothesis.
(a) As an apparently more primitive RNA-based surveil-
lance system, the RNA silencing pathway is not
only operational in mammalian cells, but there is evi-
dence that it is part of the mammalian innate antiviral
immunity. For example, the NS1 and E3L proteins en-
coded by mammalian viruses (inﬂuenza and vaccinia
viruses) function in mammalian hosts as inhibitors of
the innate antiviral response regulated by the IFN sys-
tem, which represents one of the ﬁrst lines of defense
against viral infections [47]. These proteins were shown
recently by Li et al. [9] to act as suppressors of RNA
silencing.
(b) However, it is well known that the protein-based immune
system is the major antiviral mechanism in vertebrates
and that the RNA silencing machinery seems to be some-
how defective since no direct evidence has been found to
support a strong natural antiviral activity of RNAi. Thus,
it is conceivable that RNA silencing provided the impetus
for the evolution of more eﬀective antiviral systems. The
induction of an IFN response by siRNAs has been re-
ported in diﬀerentiated mammalian cells [6,7]. This sug-
gests that siRNAs may have widespread and complex
eﬀects beyond the selective silencing of target genes. Be-
cause of the very restricted speciﬁcity of siRNAs, the
RNA silencing system could have been selected against
in evolution but have laid the foundation for the evolu-
tion of a more eﬃcient rapidly acting immunity mecha-
nism, such as the IFN system.
(c) From a theoretical point of view it is understandable that
there should have evolved a mechanism that responded to
a range of foreign entities to replace. RNA silencing is
triggered by siRNAs, since these latter are severely re-
stricted in structure. By contrast there is a wide range
of eﬀectors of the IFN response including envelope glyco-
proteins, CpG motifs, random dsDNAs or dsRNAs, etc.
Moreover, RNA silencing occurs in the cytoplasm,
whereas rapid and direct recognition of eﬀectors by cellu-
lar receptors on the cell membrane leading to the expres-
sion of IFN genes, is a key property of protein-based
immune systems.
(d) IFNs have been identiﬁed in non-mammalian vertebrates
such as chicken and ﬁsh, suggesting that the IFN re-
sponse as an antiviral defense appeared prior to the evo-
lution of the more sophisticated protein-based immune
systems. Gobel et al. [48] reported that release of IFN-c
by CD4+ T cells of the chicken can be stimulated by inter-
leukin 18 (IL-18). They therefore suggested that a fully
functional IL-18-IFN-c system arose before divergence
of birds and mammals from a common ancestor 300–
350 million years ago [49]. Interestingly, a recent study re-
vealed that high titers of a type I IFN were produced in
ﬁsh in response to infection with UV-activated grass carp
hemorrhagic virus (GCHV) [50].(e) Later, in vertebrates, IFNs became involved in numerous
immune interactions as inducers, regulators, and eﬀectors
of both innate and adaptive antiviral mechanisms. IFN-
a/b and IFN-c inﬂuence the activities of macrophages,
NK cells, dendritic cells (DC), and T cells by enhancing
antigen presentation, cell traﬃcking, cell diﬀerentiation
and expression proﬁles, ultimately enhancing and pro-
longing antiviral eﬀector functions [8].
(f) Importantly, Sledz et al. [6] have shown, using cell lines
deﬁcient in speciﬁc components of IFN action, that the
RNAi mechanism itself is independent of the IFN system.
Similarly the IFN system as an innate antiviral mecha-
nism can act independently of protein-based immune sys-
tems in vertebrates. It is therefore quite possible for the
IFN system to have served as an intermediate antiviral
mechanism during evolution.5. Outlook: A challenging opportunity for RNA silencing
The discovery of RNA silencing machinery promises to open
up two major avenues of investigation. First, it raises the
opportunity of developing novel therapeutic approaches. This
conclusion derives in essence from the natural antiviral poten-
tial of RNA silencing. Second, RNAi is now routinely used in
reverse genetic approaches to study gene functions. However,
there remain many challenges, as described elsewhere [10]. Sev-
eral critical problems will need to be addressed before a fully
successful outcome can be achieved; these include: stabilization
and enhancement of RNA silencing, improved siRNA deliv-
ery, systemic eﬀects and target mutation. Fortunately, recent
studies suggest that these hurdles can be overcome [35,36,51–
56].
In addition, RNA silencing may provide a key to under-
standing the evolution of modern cells (bacterial, archeal,
and eukaryotic cells). Several theories have already been pro-
posed in this area [57]. Typically, primitive attempts to model
cellular evolution focus on the fundamentally diﬀerent types of
genetic machinery involved in information processing, namely
translation, transcription, and genome structure and replica-
tion. After biology entered the genomic era in the 1990s, hor-
izontal gene transfer (HGT) was recognized as an evolutionary
force comparable in power to classical vertical evolutionary
mechanisms [58]. RNA silencing and related cellular defenses
against alien genetic material could also have played a part
in evolutionary strategies.6. Conclusions
We have summarized accumulating evidence that RNA
silencing acted as a natural antiviral mechanism during the
evolution of life and that a legacy of it remains in vertebrates.
Furthermore, we have argued that the existence of the IFN re-
sponse could account for both the decline in importance of
RNA silencing machinery in the vertebrate kingdom and the
development of protein-based immune systems. Although
more decisive evidence for a natural antiviral role of RNA
silencing and its synergistic interaction with the protein-based
immune system may be anticipated from studies of a variety of
viruses in vertebrates, an overall picture of the interaction of
W. Chen et al. / FEBS Letters 579 (2005) 2267–2272 2271antiviral mechanisms is beginning to emerge. As mentioned
above, we believe that antiviral strategies based on a combina-
tion of nucleic acid-based and protein-based immune systems
would be more eﬀective than either alone.
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